

Vienna, Austria

Annual Congress of the
European Association of Nuclear Medicine

October 21 – 25, 2017
Vienna, Austria

Lunch Symposium – Eli Lilly and Company
Tuesday, October 24, 2017, 13:00-14:20, Hall G1



Session Title

**Amyloid and Tau imaging in Alzheimer's Disease: What we have learned from the use of PET
Neuroimaging in clinical trials**

Programme

- 13:00-13:05 **Welcome and introduction**
Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)
- 13:05-13:25 **Quantitation and its role in Amyvid scan interpretation**
Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)
- 13:25-13:45 **Clinical utility of biomarkers in making a diagnosis of patients with cognitive decline**
Michael Devous, Sr., PhD, FSNMMI (Pennsylvania, United States of America)
- 13:45 – 14:05 **The incremental diagnostic value of Amyloid PET in memory clinics**
Giovanni Frisoni, MD (Geneva, Switzerland)
- 14:05-14:20 **Questions and answers**
All
- 14.20 **Summary & closing remarks**
Giovanni Frisoni, MD (Geneva, Switzerland)